FY2026 Earnings Forecast for Exagen Issued By William Blair

Exagen Inc. (NASDAQ:XGN) – Investment analysts at William Blair issued their FY2026 earnings per share estimates for shares of Exagen in a report issued on Wednesday, March 12th. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of ($0.23) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

XGN has been the topic of several other reports. Canaccord Genuity Group raised their price objective on Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Exagen in a research note on Monday, January 13th.

Exagen Price Performance

Shares of NASDAQ:XGN opened at $3.35 on Thursday. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54. The stock’s fifty day simple moving average is $3.78 and its two-hundred day simple moving average is $3.57. Exagen has a 1-year low of $1.30 and a 1-year high of $6.22. The stock has a market cap of $59.08 million, a PE ratio of -3.56 and a beta of 1.40.

Institutional Investors Weigh In On Exagen

Hedge funds have recently made changes to their positions in the business. Creative Planning bought a new stake in shares of Exagen during the 3rd quarter worth $110,000. Palumbo Wealth Management LLC raised its stake in shares of Exagen by 13.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock worth $355,000 after purchasing an additional 10,340 shares during the period. Verus Capital Partners LLC bought a new stake in shares of Exagen during the 3rd quarter worth $39,000. Stonepine Capital Management LLC raised its stake in shares of Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after purchasing an additional 2,630 shares during the period. 75.25% of the stock is currently owned by institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).